Drug Trial Radar · NCT06328608
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
22
Planned (sponsor's estimate)
Start
Jul 29, 2025
Primary completion
Oct 2028
Study completion Apr 2031
Sponsor
- Lead sponsor
- Chiesi Farmaceutici S.p.A.Industry
- Sponsor type
- Industry
- Collaborators
- ICON plc
- First posted
- Mar 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents with Fabry Disease.
Conditions
- Fabry Disease
Interventions
PRX-102 1 mg/kg every two weeksDrug
Drug: PRX-102 1 mg/kg every two weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment Emergent Adverse Events (TEAEs)Time frame: 12 Months
- Incidence of Infusion Related Reactions (IRRs)Time frame: 12 Months
- Incidence of Injection site reactions (ISRs)Time frame: 12 Months
- Change in Tanner stageTime frame: Baseline and 12 Months
- Change from baseline of 12-lead ECG quantitative parameters: Mean Heart RateTime frame: Baseline and 12 Months
- Change from baseline of 12-lead ECG quantitative parameters: PR IntervalTime frame: Baseline and 12 Months
- Change from baseline of 12-lead ECG quantitative parameters: QRS DurationTime frame: Baseline and 12 Months
- Change from baseline of 12-lead ECG quantitative parameters: QT IntervalTime frame: Baseline and 12 Months
- Change from baseline of 12-lead ECG quantitative parameters: QTc IntervalTime frame: Baseline and 12 Months
- Change from baseline of 12-lead ECG quantitative parameters: ST SegmentTime frame: Baseline and 12 Months
- Incidence of treatment-emergent Anti-Drug Antibodies (ADAs)Time frame: Baseline and 12 Months
- Incidence of premedication use at each visit and change of infusion premedications from baselineTime frame: Baseline and 12 Months
- Pharmacokinetics: Time to maximum plasma concentration (tmax)Time frame: Stage I - Baseline, week 2, week 4, week 12, week 26 and week 52; Stage II -Baseline, week 12, week 26 and week 52]
- Pharmacokinetic : Area under the plasma concentration-time curve from time 0 to time t (AUC0 t)Time frame: Stage I - Baseline, week 2, week 4, week 12, week 26 and week 52; Stage II -Baseline, week 12, week 26 and week 52]
- Pharmacokinetics: Area under the curve from time 0 to 2 weeks (AUC0-2wk)Time frame: Stage I - Baseline, week 2, week 4, week 12, week 26 and week 52; Stage II -Baseline, week 12, week 26 and week 52]
- Pharmacokinetics: Area under the curve from time 0 to infinity (AUC0-∞)Time frame: Stage I - Baseline, week 2, week 4, week 12, week 26 and week 52; Stage II -Baseline, week 12, week 26 and week 52]
- Pharmacokinetics: Terminal half-life (t1/2)Time frame: Baseline, week 2, week 4, week 12, week 26 and week 52]
- Pharmacokinetics: Area under the curve over a dosing interval (AUCτ)Time frame: Baseline, week 2, week 4, week 12, week 26 and week 52; Stage II -Baseline, week 12, week 26 and week 52]
- Pharmacokinetics: Observed drug concentration at the end of the dosing interval (Cτ)Time frame: Stage I - Baseline, week 2, week 4, week 12, week 26 and week 52; Stage II -Baseline, week 12, week 26 and week 52]
- Pharmacokinetics: Clearance (Cl)Time frame: Stage I - Baseline, week 2, week 4, week 12, week 26 and week 52; Stage II -Baseline, week 12, week 26 and week 52]
- Pharmacokinetics: Volume of distribution (Vz)Time frame: Stage I - Baseline, week 2, week 4, week 12, week 26 and week 52; Stage II -Baseline, week 12, week 26 and week 52]
- Change in eGFRTime frame: Baseline and 12 Months
- Change in annualized eGFR slopeTime frame: Baseline and 12 Months
- Change in urine albumin levelsTime frame: Baseline and 12 Months
- Change in urine protein levelsTime frame: Baseline and 12 Months
- Change from baseline in LVMi as assessed by echocardiogramTime frame: Baseline and 12 Months
- Change from baseline in LVMi as assessed by echocardiogramTime frame: Baseline and 12 Months
- Change from baseline in LVMi as assessed by echocardiogramTime frame: Baseline and 12 Months
- Change from baseline in LVMi as assessed by echocardiogramTime frame: Baseline and 12 Months
- Change from baseline in LVMi as assessed by echocardiogramTime frame: Baseline and 12 Months
- Incidence of any cardiac arrythmias as assessed by Holter ECGTime frame: Baseline and 12 Months
- Change in plasma levels of cardiac biomarkersTime frame: Baseline and 12 Months
- Change in plasma level of Gb3 concentration (nM)Time frame: Baseline and 12 Months
- Change in plasma level of lyso-Gb3 (nM)Time frame: Baseline and 12 Months
- Change in urine level of lyso-Gb3 (nM)Time frame: Baseline and 12 Months
- Incidence of change from baseline in the number of different pain medicationsTime frame: Baseline and 12 Months
- Incidence of Fabry Clinical EventsTime frame: 12 Months
- Change from baseline of Mainz Severity Score Index (MSSI) scoresTime frame: Baseline and 12 Months
- Change from baseline of PedsQL-GI (or GSRS for subjects who reaches 18 yrs of age) scoresTime frame: Baseline and 12 Months
- Change from baseline of FPHPQ scoresTime frame: Baseline and 12 Months
- Change from baseline of PedsQL-PPQ (or BPI-SF for subjects who reaches 18 yrs of age) scoresTime frame: Baseline and 12 Months
- Change from baseline of EQ-5D-Y (or EQ-5D-5L for subjects who reaches 18 yrs of age) scoresTime frame: Baseline and 12 Months
Locations
12 sites in 6 countries. Site status is shown where the registry gives one.
Phoenix Children's
Phoenix, Arizona · Recruiting
Emory Genetics Clinical Trials Center
Atlanta, Georgia · Recruiting
University of Iowa
Iowa City, Iowa · Recruiting
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio · Recruiting
University of Utah
Salt Lake City, Utah · Recruiting
Lysosomal and Rare Disorders Research and Treatment Center Inc
Fairfax, Virginia · Recruiting
UK für Kinder- und Jugendheilkunde der PMU Salzburg
Salzburg, Austria · Recruiting
Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Pellegrin
Bordeaux, France · Recruiting
Hopital Arnaud de Villeneuve
Montpellier, France · Recruiting
Haukeland Universitetssjukehus
Bergen, Norway · Recruiting
Hospital Clinico Universitario De Santiago De Compostela
Santiago de Compostela, Spain · Recruiting
Great Ormond Street Hospital for Children NHS Foundation Trust
London, United Kingdom · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.